Teriflunomide in patients with multiple sclerosis
https://doi.org/10.21518/2079-701X-2015-5-90-93
Abstract
The article discusses the prospects for the use of the new drug teriflunomide for the treatment of patients with relapsing-remitting multiple sclerosis. By now, phase II and III clinical trials are completed which demonstrated good tolerability, efficacy and relative safety of teriflunomide. The TEMSO and TOWER trials showed a decrease in the incidence of relapse which was a reason for hospitalization (by 59 and 37%, respectively), as well as in the incidence of exacerbations requiring treatment with corticosteroids (by 34 and 36%, respectively).
About the Authors
N. Y. Lasch
the Russian National Research Medical University named after N.I. Pirogov, Moscow
Russian Federation
Russian Federation
A. N. Boyko
the Russian National Research Medical University named after N.I. Pirogov, Moscow
Russian Federation
Russian Federation
References
1. Рассеянный склероз. Клиническое руководство. Под ред. Е.И. Гусева, И.А. Завалишина, А.Н. Бойко. М.: Реал Тайм, 2011.
2. Бойко А.Н. Патогенетическое лечение рассеянного склероза и других аутоиммунных заболеваний нервной системы. В кн. «Аутоиммунные заболевания в неврологии». Клиническое руководство под ред. ИА. Завалишина, М.А. Пирадова, А.Н. Бойко, С.С. Никитина, Н.Н. Спирина и А.В. Переседовой. РООИ «Здоровье человека». М., 2014, 1: 285-344.
3. Рекомендации Всероссийского общества неврологов для проведения курса лечения препаратами, изменяющими течение рассеянного склероза. Журн. неврол. и психиат., 2009, 109 (7), 2: 129-134.
4. Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol Sci, 2008, 29(2): 253-255.
5. Freedman MS. Induction vs. escalation of therapy for multiple sclerosis: evidence. Eurol Sci, 2008, 29(2): 250-252.
6. Инструкция по медицинскому применению препарата Абаджио. 2014.
7. Osiri M, Shea B, Robinson V et al. Leflunomide for treating rheumatoid arthritis. Cochrane database of systemic reviews (Online) (1): CD002047.
8. Limsakin T, Menguy-Vacheron F. Pharmacokinetics of oral teriflunomide, a novel oral disease modifying agent under investigation for the treatment of MS. Presented at the Annual Meeting of the Americal Academy of Neurology (ANN) 2010.
9. O'Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of terifluno-mide in multiple sclerosis with relapses. Neurology, 2006, 66(6): 894-900.
10. Бойко О.Б., Столяров И.А., Петров А.М., Бойко А.Н. Терифлуномид - новый пероральный препарат, изменяющий течение рассеянного склероза (обзор). Журн. неврол. и психиат., 2013, 10/2: 78-81.
11. Kieiseier B, Benamor M, Truffinet P. Pregnancy outcomes for female patients and partners of male patients in the teriflunomide clinical development program. 2014 Joint ACTRIMS -ECTRIMS Meeting, September 10-13, 2014, Boston, MA, USA.
12. Kieiseier B, Struve O, Benamor M et al. Upated pregnancy outcomes from teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database. Mult Scler, 2013, 19: 74.
13. Kieiseier B, Benamor M, Truffinet P. Pregnancy outcomes for female patients and partners of male patients in the teriflunomide clinical development program. 2014 Joint ACTRIMS -ECTRIMS Meeting, September 10-13, 2014, Boston, MA, USA.
14. O'Connor P, Wolinsky JS, Confavreux C et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med., 2011,365: 1293-303.
15. Confavreux C, O'Connor P, Comi G et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Mar; 13(3): 247-56.
16. Harrison S, Bergfeld W. Diffuse hair loss: its triggers and management. Cleve Clin J Med. 2009, 76(6): 361-367.
17. Freedman M, Wolinsky J, Comi G et al. Safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis treated with inter-feron beta. Presented at: 8th World Congress on Controversies in Neurology 2014. Berlin, Germany.
18. Davenport L, Czich A, Turpault S. Teriflunomide: no effects on sperm DNA. Mult Scler 2013, 19, 559: 1187.
Review
For citations:
Lasch NY, Boyko AN. Teriflunomide in patients with multiple sclerosis. Meditsinskiy sovet = Medical Council. 2015;(5):90-93. (In Russ.) https://doi.org/10.21518/2079-701X-2015-5-90-93
Views:
520
Email this article 